About this document
Imatinib Standard Dose in CML Treatment by Gustavo Catarina is a document available to read on EtoBox.
This study investigates the relationship between the plasma concentration of imatinib and clinical responses in patients with chronic myeloid leukemia (CML). The findings suggest that adherence to the standard dose of imatinib (400 mg/day) is crucial for achieving a complete molecular response, while plasma concentration does not significantly correlate with clinical outcomes. The results emphasize the importance of maintaining the standard dosage for better patient survival and response rates.
- Author
- Gustavo Catarina
- Language
- EN